{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:47:30Z","timestamp":1711154850361},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00108-024-01675-6","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T15:03:47Z","timestamp":1709737427000},"page":"357-364","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lebertransplantation bei viralen und autoimmunen Lebererkrankungen","Liver transplantation in viral and autoimmune liver diseases"],"prefix":"10.1007","volume":"65","author":[{"given":"Christian M.","family":"Lange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias J.","family":"Weism\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P.","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"1675_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver (2016) EASL Clinical Practice Guidelines: Liver transplantation. J\u00a0Hepatol 64:433\u2013485","journal-title":"J Hepatol"},{"key":"1675_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","volume":"69","author":"European Association for the Study of the Liver.","year":"2018","unstructured":"European Association for the Study of the Liver., European Association for the Study of the L. (2018) EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J\u00a0Hepatol 69:154\u2013181","journal-title":"J Hepatol"},{"key":"1675_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/a-1498-2512","volume":"59","author":"M Cornberg","year":"2021","unstructured":"Cornberg\u00a0M, Sandmann\u00a0L, Protzer\u00a0U et\u00a0al (2021) S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z\u00a0Gastroenterol 59:691\u2013776","journal-title":"Z Gastroenterol"},{"key":"1675_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(19)31894-X","volume":"394","author":"RT Stravitz","year":"2019","unstructured":"Stravitz\u00a0RT, Lee\u00a0WM (2019) Acute liver failure. Lancet 394:869\u2013881","journal-title":"Lancet"},{"key":"1675_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-023-05948-2","volume":"617","author":"A Ho","year":"2023","unstructured":"Ho\u00a0A, Orton\u00a0R, Tayler\u00a0R et\u00a0al (2023) Adeno-associated virus 2 infection in children with non-A\u2011E hepatitis. Nature 617:555\u2013563","journal-title":"Nature"},{"key":"1675_CR6","unstructured":"RdBz Lebertransplantation. https:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/BAEK\/Ueber_uns\/Richtlinien_Leitlinien_Empfehlungen\/RiliOrgaWlOvLeberTx20230912.pdf"},{"key":"1675_CR7","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","volume":"68","author":"European Association for the Study of the Liver.","year":"2018","unstructured":"European Association for the Study of the Liver. (2018) EASL Clinical Practice Guidelines on hepatitis\u00a0E virus infection. J\u00a0Hepatol 68:1256\u20131271","journal-title":"J Hepatol"},{"key":"1675_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429","volume":"389","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer\u00a0H, Aleman\u00a0S, Brunetto\u00a0MR et\u00a0al (2023) A\u00a0Phase\u00a03, Randomized Trial of Bulevirtide in Chronic Hepatitis\u00a0D. N\u00a0Engl J Med 389:22\u201332","journal-title":"N Engl J Med"},{"key":"1675_CR9","unstructured":"Berg T, Aehling N, Bruns T et\u00a0al S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft f\u00fcr Allgemein- und Viszeralchirurgie (DGAV)"},{"key":"1675_CR10","first-page":"1100","volume":"58","author":"C Sarrazin","year":"2020","unstructured":"Sarrazin\u00a0C, Zimmermann\u00a0T, Berg\u00a0T et\u00a0al (2020) Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. Z\u00a0Gastroenterol 58:1100\u20131138","journal-title":"Z Gastroenterol"},{"key":"1675_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jhep.2022.01.022","volume":"77","author":"AJ Montano-Loza","year":"2022","unstructured":"Montano-Loza\u00a0AJ, Ronca\u00a0V, Ebadi\u00a0M et\u00a0al (2022) Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. J\u00a0Hepatol 77:84\u201397","journal-title":"J Hepatol"},{"key":"1675_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1055\/s-0043-120199","volume":"55","author":"Strassburg","year":"2017","unstructured":"Strassburg, Deutsche Gesellschaft fur Gastroenterologie V\u2011uS, Deutsche Gesellschaft fur Innere M, Deutsche MCCuV et\u00a0al (2017) Practice guideline autoimmune liver diseases\u2014AWMF-Reg. No. 021-27. Z\u00a0Gastroenterol 55:1135\u20131226","journal-title":"Z Gastroenterol"},{"key":"1675_CR13","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/lt.25739","volume":"26","author":"M Heinemann","year":"2020","unstructured":"Heinemann\u00a0M, Adam\u00a0R, Berenguer\u00a0M et\u00a0al (2020) Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. Liver Transpl 26:866\u2013877","journal-title":"Liver Transpl"},{"key":"1675_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1055\/s-0037-1608655","volume":"37","author":"EF Martin","year":"2017","unstructured":"Martin\u00a0EF, Levy\u00a0C (2017) Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis. Semin Liver Dis 37:305\u2013313","journal-title":"Semin Liver Dis"},{"key":"1675_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2010.02.030","volume":"53","author":"G Rudolph","year":"2010","unstructured":"Rudolph\u00a0G, Gotthardt\u00a0D, Kloeters-Plachky\u00a0P et\u00a0al (2010) In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J\u00a0Hepatol 53:313\u2013317","journal-title":"J Hepatol"},{"key":"1675_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","volume":"102","author":"JJ Tischendorf","year":"2007","unstructured":"Tischendorf\u00a0JJ, Hecker\u00a0H, Kruger\u00a0M et\u00a0al (2007) Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A\u00a0single center study. Am J Gastroenterol 102:107\u2013114","journal-title":"Am J Gastroenterol"},{"key":"1675_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","volume":"75","author":"WR Kim","year":"2000","unstructured":"Kim\u00a0WR, Therneau\u00a0TM, Wiesner\u00a0RH et\u00a0al (2000) A\u00a0revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75:688\u2013694","journal-title":"Mayo Clin Proc"},{"key":"1675_CR18","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","volume":"67","author":"EM de Vries","year":"2018","unstructured":"de Vries\u00a0EM, Wang\u00a0J, Williamson\u00a0KD et\u00a0al (2018) A\u00a0novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut 67:1864\u20131869","journal-title":"Gut"},{"key":"1675_CR19","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/hep.30479","volume":"69","author":"EC Goode","year":"2019","unstructured":"Goode\u00a0EC, Clark\u00a0AB, Mells\u00a0GF et\u00a0al (2019) Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a\u00a0Risk Scoring System. Hepatology 69:2120\u20132135","journal-title":"Hepatology"},{"key":"1675_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/lt.24350","volume":"22","author":"T Hildebrand","year":"2016","unstructured":"Hildebrand\u00a0T, Pannicke\u00a0N, Dechene\u00a0A et\u00a0al (2016) Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A\u00a0retrospective multicenter analysis. Liver Transpl 22:42\u201352","journal-title":"Liver Transpl"},{"key":"1675_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","volume":"63","author":"R Ravikumar","year":"2015","unstructured":"Ravikumar\u00a0R, Tsochatzis\u00a0E, Jose\u00a0S et\u00a0al (2015) Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J\u00a0Hepatol 63:1139\u20131146","journal-title":"J Hepatol"},{"key":"1675_CR22","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.3748\/wjg.v24.i28.3171","volume":"24","author":"BM Buchholz","year":"2018","unstructured":"Buchholz\u00a0BM, Lykoudis\u00a0PM, Ravikumar\u00a0R et\u00a0al (2018) Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients. World J Gastroenterol 24:3171\u20133180","journal-title":"World J Gastroenterol"},{"key":"1675_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J\u00a0Hepatol 67:145\u2013172","journal-title":"J Hepatol"},{"key":"1675_CR24","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/lt.25321","volume":"24","author":"C Levy","year":"2018","unstructured":"Levy\u00a0C (2018) Primary Biliary Cholangitis Guidance Update: Implications for Liver Transplantation. Liver Transpl 24:1508\u20131511","journal-title":"Liver Transpl"},{"key":"1675_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.1840100102","volume":"10","author":"ER Dickson","year":"1989","unstructured":"Dickson\u00a0ER, Grambsch\u00a0PM, Fleming\u00a0TR et\u00a0al (1989) Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 10:1\u20137","journal-title":"Hepatology"},{"key":"1675_CR26","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers\u00a0WJ, Hirschfield\u00a0GM, Corpechot\u00a0C et\u00a0al (2015) Development and Validation of a\u00a0Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology 149:1804\u20131812 e4","journal-title":"Gastroenterology"},{"key":"1675_CR27","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/hep.28017","volume":"63","author":"M Carbone","year":"2016","unstructured":"Carbone\u00a0M, Sharp\u00a0SJ, Flack\u00a0S et\u00a0al (2016) The UK-PBC risk scores: Derivation and validation of a\u00a0scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 63:930\u2013950","journal-title":"Hepatology"},{"key":"1675_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1053\/jlts.2000.6503","volume":"6","author":"WR Kim","year":"2000","unstructured":"Kim\u00a0WR, Wiesner\u00a0RH, Poerucha\u00a0JJ, Therneau\u00a0TM, Benson\u00a0JT, Krom\u00a0RA, Dickson\u00a0ER (2000) Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transpl 6:489\u2013494","journal-title":"Liver Transpl"},{"issue":"Suppl 1","key":"1675_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/ajt.14559","volume":"18","author":"WR Kim","year":"2018","unstructured":"Kim\u00a0WR, Lake\u00a0JR, Smith\u00a0JM et\u00a0al (2018) OPTN\/SRTR 2016 Annual Data Report: Liver. Am J Transplant 18(Suppl 1):172\u2013253","journal-title":"Am J Transplant"},{"key":"1675_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2018.10.001","volume":"156","author":"AJ Montano-Loza","year":"2019","unstructured":"Montano-Loza\u00a0AJ, Hansen\u00a0BE, Corpechot\u00a0C et\u00a0al (2019) Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology 156:96\u2013107 e1","journal-title":"Gastroenterology"},{"key":"1675_CR31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1600-6143.2009.03006.x","volume":"10","author":"AJ Montano-Loza","year":"2010","unstructured":"Montano-Loza\u00a0AJ, Wasilenko\u00a0S, Bintner\u00a0J et\u00a0al (2010) Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transplant 10:852\u2013858","journal-title":"Am J Transplant"},{"key":"1675_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1432-2277.2007.00628.x","volume":"21","author":"IA Rowe","year":"2008","unstructured":"Rowe\u00a0IA, Webb\u00a0K, Gunson\u00a0BK et\u00a0al (2008) The impact of disease recurrence on graft survival following liver transplantation: a\u00a0single centre experience. Transpl Int 21:459\u2013465","journal-title":"Transpl Int"},{"key":"1675_CR33","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","volume":"63","author":"A Bosch","year":"2015","unstructured":"Bosch\u00a0A, Dumortier\u00a0J, Maucort-Boulch\u00a0D et\u00a0al (2015) Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a\u00a0lower risk of disease recurrence. J\u00a0Hepatol 63:1449\u20131458","journal-title":"J Hepatol"},{"key":"1675_CR34","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/lt.25935","volume":"27","author":"MR Pedersen","year":"2021","unstructured":"Pedersen\u00a0MR, Greenan\u00a0G, Arora\u00a0S et\u00a0al (2021) Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A\u00a0Meta-Analysis. Liver Transpl 27:866\u2013875","journal-title":"Liver Transpl"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01675-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:04:01Z","timestamp":1711105441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01675-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1675"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01675-6","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"1 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.M.\u00a0Lange: Vortrags- und Beraterhonorare von AbbVie, AstraZeneca, Boston Scientific, CSL Behring, Eisai, Falk, Gore, MSD, Norgine, Roche, Sobi, Shionogi. T.J.\u00a0Weism\u00fcller: Vortrags- und Beraterhonorare von Boston Scientific, Fujifim und Micro-Tech Europe. C.P.\u00a0Strassburg: Vortrags- und Beraterhonorare: Falk Pharma, AstraZeneca, AbbVie, Gilead, Eisai, Schwabe, Intercept; Unterst\u00fctzung f\u00fcr Fortbildungen: Janssen, Falk Foundation, Intercept, Tillotts, Eisai, AbbVie, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}